Preoperative Breast MRI accurately detects otherwise occult cancer

October 30, 2015

administration of FG-3019 was reported to reverse fibrotic processes in a model of radiation-induced lung fibrosis at the 2010 annual meeting of the American Thoracic Society (also see below "About CTGF and Idiopathic Pulmonary Fibrosis");preventative and curative effects resulting from genetic blockade of CTGF using siRNA were reported in a model of liver fibrosis at the 2008 annual meeting of the American Association for the Study of Liver Diseases and in a subsequent journal article; and reversal of vascular remodeling using FG-3019 in a model of type 1 diabetes mellitus was reported at the 2006 annual meeting of the American Diabetes Association.

"What sets our program apart is that FG-3019 targets the central mediator of fibrosis whereas other approaches target modification of indirect fibrogenic factors or a single point in the process," said Thomas B. Neff, Chief Executive Officer of FibroGen. "CTGF is at the center of multiple positive feedback loops that, irrespective of etiology, drive the fibrosis process. We believe anti-CTGF is the only currently known therapeutic approach having potential to alter disease progression."

The phase 2 study is expected to enroll 48 patients with progressive IPF, who will receive intravenous infusions of FG-3019 every 3 weeks for 45 weeks. Safety, tolerability, and the effect of FG-3019 on extent of lung fibrosis (as measured by CT scan), lung function, and shortness of breath will be assessed.

"This is an important study that will examine the ability of anti-CTGF therapy to attenuate fibrosis and improve lung function in patients with IPF," said Frank Valone, MD, Chief Medical Officer of FibroGen. "Based on evidence from nonclinical studies that FG-3019 can reverse the process of lung fibrosis, we are hopeful that FG-3019 will prove clinically beneficial in patients with IPF."

SOURCE FibroGen, Inc.